Abemaciclib Approval Expands Initial Treatment Options for Advanced Breast Cancer

FDA has approved the CDK4/6 inhibitor abemaciclib (Verzenio) as a first-line treatment in some women with advanced or metastatic breast cancer. Under the approval, the drug must be used in combination with an aromatase inhibitor.

Cancer Currents: An NCI Cancer Research Blog